| 前收盘价格 | 48.84 |
| 成交量 | 21,416,811 |
| 预期市盈率 (P/E Forward) | 23.42 |
| 价格/销量 (P/S) | 8.01 |
| 股市价格/股市净资产 (P/B) | 3.64 |
| 52周波幅 |
| 营业毛利率 | 17.97% |
| 营业利益率 (TTM) | 27.38% |
| 稀释每股收益 (EPS TTM) | 0.850 |
| 季度收入增长率 (YOY) | 18.30% |
| 季度盈利增长率 (YOY) | 63.90% |
| 总债务/股东权益 (D/E MRQ) | 10.86% |
| 流动比率 (MRQ) | 2.73 |
| 营业现金流 (OCF TTM) | 5.22 B |
| 杠杆自由现金流 (LFCF TTM) | -2.30 B |
| 资产报酬率 (ROA TTM) | 5.05% |
| 股东权益报酬率 (ROE TTM) | 8.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | WUXI BIO | - | - |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.44 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| WUXI BIO | - | - | - | 3.64 |
| INNOVENT BIO | - | - | - | 7.57 |
| SBP GROUP | - | 1.15% | - | 2.47 |
| AKESO | - | - | - | 8.83 |
| ASCENTAGE | - | - | - | 19.80 |
| KEYMED BIO-B | - | - | - | 5.00 |
|
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 13.07% |
| 机构持股比例 | 35.91% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合